

DR REDDYS LABORATORIES LTD  
Form 20-F/A  
July 12, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 20-F/A**

**Amendment No. 1**

**..REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES  
EXCHANGE ACT OF 1934**

**OR**

**ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF  
p 1934**

**For the Fiscal Year Ended March 31, 2018**

**OR**

**..TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT  
OF 1934**

**OR**

**..SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Commission File Number: 1-15182**

**DR. REDDY'S LABORATORIES LIMITED**

(Exact name of Registrant as specified in its charter)

**Not Applicable**                      **TELANGANA, INDIA**  
(Translation of Registrant's name(Jurisdiction of incorporation or  
into English)                      organization)

**8-2-337, Road No. 3, Banjara Hills**

**Hyderabad, Telangana 500 034, India**

**+91-40-49002900**

(Address of principal executive offices)

Saumen Chakraborty, *Chief Financial Officer*, +91-40-49002004, saumenc@drreddys.com

8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500 034, India

(Name, telephone, e-mail and/or facsimile number and address of company contact person)

Securities registered or to be registered pursuant to Section 12(b) of the Act.

| <b>Title of Each Class</b>  | <b>Name of Each Exchange on which Registered</b> |
|---|--|
| <b>American depository shares, each representing one equity share</b> | <b>New York Stock Exchange</b>                   |

**Equity Shares\***

\*

**Not for trading, but only in connection with the registration of American depositary shares, pursuant to the requirements of the Securities and Exchange Commission.**

Securities registered or to be registered pursuant to Section 12(g) of the Act. None.

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. None.

Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report.

**165,910,907 Equity Shares**

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes  No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Yes  No

Note — Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth company. See the definitions of “accelerated filer”, “large accelerated filer” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Emerging growth company

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards<sup>†</sup> provided pursuant to Section 13(a) of the Exchange Act.

<sup>†</sup> The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP  International Financial Reporting Standards as issued  Other   
by the International Accounting Standards Board

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

Item 17  Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).

Yes  No

## **Explanatory Note**

This Amendment No. 1 to the Annual Report on Form 20-F of Dr. Reddy's Laboratories Limited ("Dr. Reddy's") amends its Annual Report on Form 20-F for the year ended March 31, 2018, which was filed with the Securities and Exchange Commission on June 15, 2018. Dr. Reddy's is filing this Amendment No. 1 solely to furnish the Interactive Data File discloser as Exhibit 101 in accordance with Rule 405 of Regulation S-T, which was omitted from the Form 20-F in accordance with the 30-day grace period provided under Rule 405(a)(2)(ii) of Regulation S-T. Exhibit 101 includes information in eXtensible Business Reporting Language ("XBRL").

Except as described above, this Amendment No. 1 does not amend any information set forth in the Original 20-F, and Dr. Reddy's has not updated disclosures included therein to reflect any events that may have occurred subsequent to June 15, 2018.

**ITEM 19. EXHIBITS**

| <b>Exhibit<br/>number</b> | <b>Description of Exhibit</b>                                 | <b>Footnotes</b> |
|---------------------------|---|------------------|
| <u>101.INS</u>            | <u>XBRL Instance Document</u>                                 | <u>(1)</u>       |
| <u>101.SCH</u>            | <u>XBRL Taxonomy Extension Schema Document</u>                | <u>(1)</u>       |
| <u>101.CAL</u>            | <u>XBRL Taxonomy Extension Calculation Linkbase Document</u>  | <u>(1)</u>       |
| <u>101.DEF</u>            | <u>XBRL Taxonomy Extension Definition Linkbase Document</u>   | <u>(1)</u>       |
| <u>101.LAB</u>            | <u>XBRL Taxonomy Extension Label Linkbase Document</u>        | <u>(1)</u>       |
| <u>101.PRE</u>            | <u>XBRL Taxonomy Extension Presentation Linkbase Document</u> | <u>(1)</u>       |

<sup>(1)</sup> In accordance with Rule 402 of Regulation S-T, the information in these exhibits shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**SIGNATURE**

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Amendment No. 1 to the Annual Report on Form 20-F on its behalf.

Hyderabad, India /s/ Saumen Chakraborty  
Saumen Chakraborty

Date: July 12, 2018 President and Chief Financial Officer